M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
76 deals · US$92bndisclosed · Pharma · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Mar 2026 | Novartis India | Novartis AG | WaveRise Investments | Acquisition | Announced | – | Pharma | Freshfields (sell-side) |
| Mar 2026 | Corstasis Therapeutics | – | Esperion Therapeutics | Acquisition | Completed | 75.0 | Pharma+1 | PJT Partners (sell-side)Arnold & Porter (sell-side)Jefferies (buy-side)Gibson Dunn (buy-side) |
| Mar 2026 | Transcend Therapeutics | – | Otsuka | Acquisition | Announced | 700.0 | Biotech+2 | Kirkland & Ellis (sell-side)Goodwin (sell-side)Centerview Partners (sell-side)Skadden, Arps, Slate, Meagher & Flom (buy-side) |
| Mar 2026 | Paratek Pharmaceuticals | – | – | Merger | Completed | – | Pharma | Skadden, Arps, Slate, Meagher & Flom |
| Mar 2026 | Manufacturing facility in Phoenix, AZ | Bristol Myers Squibb | Rovi | Asset sale | Completed | – | Pharmaceutical Manufacturing+1 | William Blair |
| Feb 2026 | AiCuris Anti-infective Cures AG | – | Veloxis Pharmaceuticals | Acquisition | Announced | 913.0 | Pharma+1 | Gibson Dunn (sell-side)Freshfields (buy-side) |
| Feb 2026 | Avadel Pharmaceuticals | – | Alkermes | Scheme | Completed | – | Pharma+1 | Goldman Sachs (sell-side)Morgan Stanley (sell-side)J.P. Morgan (buy-side) |
| Feb 2026 | Orna Therapeutics | – | Eli Lilly and Company | Acquisition | Announced | 2,400.0 | Biotech+1 | Lazard (sell-side)Goodwin (sell-side)Paul, Weiss (buy-side) |
| Feb 2026 | Apex Healthcare Berhad | – | Quadria Capital-led consortium | Acquisition | Announced | – | Pharma+1 | Latham & Watkins (buy-side) |
| Jan 2026 | TerSera Infusion Specialty Therapies Business Unit (IST) | TerSera Therapeutics | ESTEVE | Asset sale | Pending | – | Pharma | Kirkland & Ellis (sell-side)Leerink Partners (sell-side)Perella Weinberg Partners (buy-side)Arnold & Porter (buy-side) |
| Jan 2026 | Radius Health | Patient Square Capital | B-FLEXION Life Sciences | Acquisition | Announced | – | Pharma | Kirkland & Ellis (sell-side)Centerview Partners (sell-side) |
| Jan 2026 | Ventyx Biosciences | – | Eli Lilly and Company | Acquisition | Announced | 1,200.0 | Biotech+2 | Jefferies (sell-side)Moelis & Company (sell-side)Wilson Sonsini Goodrich & Rosati (sell-side)BofA Securities (buy-side)Ropes & Gray (buy-side) |
| Jan 2026 | Nivagen Pharmaceuticals | – | PAI Pharma | Acquisition | Announced | – | Pharmaceutical Manufacturing+1 | Bourne Partners (buy-side)Kirkland & Ellis (buy-side)KPMG (buy-side) |
| Jan 2026 | PTC Therapeutics' remaining royalty on Roche's Evrysdi | PTC Therapeutics | Royalty Pharma | Asset sale | Announced | 240.0 | Specialty finance and leasing+2 | Goodwin (buy-side) |
| Jan 2026 | Biogaran | Servier | BC Partners | Acquisition | Announced | – | Pharma | Lazard |
| Jan 2026 | Wonderbelly | – | Procter & Gamble | Acquisition | Completed | – | Consumer Health+1 | Perella Weinberg Partners (sell-side) |
| Jan 2026 | Lantheus SPECT business | Lantheus | SHINE Technologies | Asset sale | Announced | – | Pharma+2 | Solomon Partners (sell-side) |
| 2026 | Istituto Biochimico Italiano Giovanni Lorenzini (IBI Lorenzini) | – | ACS Dobfar | Acquisition | Announced | – | Pharmaceutical Manufacturing+1 | Lincoln International (sell-side) |
| 2026 | Egetis | – | ANI Pharmaceuticals | Acquisition | Announced | 560.0 | Pharma+1 | Centerview Partners (sell-side) |
| Dec 2025 | Dynavax Technologies | – | Sanofi | Acquisition | Announced | 2,200.0 | Biotech+1 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Cooley (sell-side)Weil, Gotshal & Manges (buy-side) |
| Dec 2025 | Amicus Therapeutics | – | BioMarin | Acquisition | Announced | 4,800.0 | Biotech+2 | Centerview Partners (sell-side)Goldman Sachs (sell-side)Kirkland & Ellis (sell-side)Morgan Stanley (buy-side)Jones Day (buy-side) |
| Dec 2025 | MindWave Innovations | – | Apimeds Pharmaceuticals US | Merger | Completed | – | Biotech+1 | Duane Morris (sell-side)Nelson Mullins Riley & Scarborough (buy-side) |
| Sep 2025 | Zentiva | Advent International | GTCR | Acquisition | Announced | – | Pharma+1 | Goldman Sachs (sell-side)PJT Partners (sell-side)Freshfields (sell-side)Barclays (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| Jul 2025 | Altanine | – | Polomar Health Services | Merger | Pending | – | Healthcare+1 | |
| Jun 2025 | Felix Pharmaceuticals Pvt | – | Advent International | Stake | Announced | – | Animal Health+2 | A&L Goodbody LLPLincoln International (sell-side)Guggenheim Securities (buy-side) |
| – | Telomir Pharmaceuticals | – | – | Merger | Announced | 47.1 | Biotech+1 |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.